Dr Reddy's launches generic cancer drug in Canada

Dr Reddy's Laboratories today said it has launched generic Azacitidine for injection, a cancer treatment drug, in the Canadian market.
The company's product, which is a generic equivalent of Vidaza, has been approved by Health Canada, Dr Reddy's Laboratories said in a statement.
"Bringing Azacitidine for Injection to the Canadian market at this time is very important for us, as well as for our customers and their patients," Dr Reddys Executive Vice President and Head of the North America Generics business Alok Sonig said.
The Hyderabad-based firm is first to market with this Azacitidine for injection in Canada, the company said.

Dr Reddy's Canada Country Manager Vinod Ramachandran said the approval and launch of Azacitidine for injection is an important milestone for the company in Canada.
"The launch of first generic Azacitidine for injection is another step in our long-term commitment to bring more cost-effective options to Canadian patients," he added.